Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Stomach Neoplasms 1Pancreatic Neoplasms 1Oligoprogressive 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Cancer Patients 1

Interventions

Nivolumab 70pembrolizumab 69cabozantinib 46Ipilimumab 38Specimen Handling 33Magnetic Resonance Spectroscopy 33lenvatinib 26Axitinib 25belzutifan 21Sunitinib 18Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × DEAE-Dextran × 1 year × Clear all
NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
6 enrolled 7 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡